sodium chloride
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | THAM | — | 1965-12-16 | fda.gov ↗ |
Trials 98 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT05634213 | Mar 2023 → Apr 2025 | cardiac valvular defect | Ottawa Heart Institute Research Corporation | Withdrawn | No outcome recorded |
| Phase 0 | NCT06139029 | Nov 2022 → Mar 2023 | acute bronchiolitis | Mardan Medical Complex | Completed | No outcome recorded |
| Phase 0 | NCT05029596 | Feb 2020 → Mar 2023 | cancer | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT03837470 | May 2019 → Feb 2020 | diastolic heart failure | Adhish Agarwal | Completed | No outcome recorded |
| Phase 0 | NCT04197245 | Jan → Jul 2019 | skin atrophy | Jinnah Postgraduate Medical Centre | Completed | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT05154968 | Nov → Dec 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04147182 | Dec 2018 → Jul 2019 | — | Dan Leibovici | Unknown | No outcome recorded |
| Phase 1 | NCT02947126 | Jan 2017 → Feb 2020 | cystic fibrosis | Tim Corcoran | Completed | No outcome recorded |
| Phase 1 | NCT02854683 | Feb 2016 → Dec 2021 | myalgic encephalomeyelitis/chronic fatigue syndrome, neurally mediated hypotension, postural orthostatic tachycardia syndrome | New York Medical College | Unknown | No outcome recorded |
| Phase 1 | NCT01094704 | Nov 2009 → May 2010 | cystic fibrosis | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 1/24 trials · 1 missed | ||||||
| Phase 1/2 | NCT06820164 | May 2025 → Jan 2027 expected | lipoma | West Virginia University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06370975 | Aug 2024 → Aug 2025 | — | Assiut University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01073787 | Jul 2010 → Nov 2012 | migraine disorder | University of Alberta | Completed | Missed primary |
| Phase 1/2 | NCT00228657 | Jul 2002 → Aug 2003 | decubitus ulcer | Bayside Health | Completed | No outcome recorded |
| Phase 28 trials · 1 missed | ||||||
| Phase 2 | NCT06471998 | Feb 2025 → Mar 2026 | chronic pain syndrome | Ramsay Santé | Completed | No outcome recorded |
| Phase 2 | NCT04344236 | Apr → May 2020 | COVID-19 | NYU Langone Health | Withdrawn | No outcome recorded |
| Phase 2 | NCT04785755 | Nov 2017 → Mar 2020 | — | Hala Abd EL-Tawab Ibrahim Radwan | Completed | No outcome recorded |
| Phase 2 | NCT01042015 | Oct 2016 → Nov 2025 | cardiac arrest | University of Maryland, Baltimore | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02142985 | Apr 2014 → Apr 2015 | — | University of Monastir | Completed | No outcome recorded |
| Phase 2 | NCT01411852 | Mar 2012 → Apr 2013 | brain injury | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT00819416 | Feb → Oct 2009 | infectious disease with sepsis | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT01293084 | Jul 2007 → Jun 2009 | cystic fibrosis | Johns Hopkins University | Completed | Missed primary |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT06558461 | Jun 2022 → May 2024 | acute bronchiolitis | Can Tho University of Medicine and Pharmacy | Completed | No outcome recorded |
| Phase 2/3 | NCT04802408 | Oct 2021 → May 2024 | COVID-19 | Milton S. Hershey Medical Center | Terminated | No outcome recorded |
| Phase 2/3 | NCT04802785 | Jun → Jul 2021 | — | Dinara Zhumanbayeva | Unknown | No outcome recorded |
| Phase 2/3 | NCT04242368 | Jul 2020 → Jul 2021 | chronic rhinosinusitis | Stanford University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT00619918 | Feb 2008 → May 2011 | bronchiolitis | Children's Hospital Los Angeles | Completed | No outcome recorded |
| Phase 2/3 | NCT00163852 | Feb 2004 → Feb 2006 | cystic fibrosis | Bayside Health | Unknown | No outcome recorded |
| Phase 313 trials · 3 met primary · 2 missed | ||||||
| Phase 3 | NCT07596329 | Sep 2026 → Nov 2027 expected | chronic kidney disease, congestive heart failure | University of Monastir | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06953674 | Jun 2025 → Jun 2029 expected | traumatic brain injury | University of Louisville | Recruiting | No outcome recorded |
| Phase 3 | NCT05084378 | Mar 2022 → Aug 2024 | periprosthetic joint infection | McMaster University | Completed | No outcome recorded |
| Phase 3 | NCT05962255 | Feb 2022 → Apr 2024 | heart failure | Wroclaw Medical University | Completed | Met primary |
| Phase 3 | NCT05121389 | Jan 2021 → Nov 2022 | ischemic stroke | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02872155 | Jul 2017 → Jul 2019 | impaired renal function disease | David Garcia Cinca | Completed | No outcome recorded |
| Phase 3 | NCT02905760 | Dec 2016 → Nov 2018 | acute myocardial infarction | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 3 | NCT03106922 | Apr 2016 → Jul 2020 | — | Alfasigma S.p.A. | Unknown | No outcome recorded |
| Phase 3 | NCT01786824 | Dec 2014 → Aug 2015 | acute kidney injury, impaired renal function disease | Nîmes University Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT02221024 | Jul 2011 → Sep 2013 | — | IRCCS Burlo Garofolo | Completed | Met primary |
| Phase 3 | NCT01365793 | Nov 2010 → Sep 2016 | brain edema, diabetic ketoacidosis | University of California, Davis | Completed | Missed primary |
| Phase 3 | NCT00734214 | Mar 2008 → Dec 2009 | — | Hamilton Health Sciences Corporation | Completed | Met primary |
| Phase 3 | NCT00318942 | Feb 2003 → Aug 2012 | — | University of Versailles | Completed | Missed primary |
| Phase 423 trials · 6 met primary · 3 missed | ||||||
| Phase 4 | NCT07447063 | Aug 2026 → Mar 2028 expected | atopic eczema | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 4 | NCT07487831 | Jul 2026 → Mar 2028 expected | atopic eczema, psoriasis | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 4 | NCT06242795 | Oct 2024 → Jun 2026 overdue | bronchiectasis | University of North Carolina, Chapel Hill | Recruiting | No outcome recorded |
| Phase 4 | NCT06441162 | Jul 2024 → May 2025 | acute bronchiolitis | NYU Langone Health | Terminated | No outcome recorded |
| Phase 4 | NCT07108881 | May → Dec 2024 | acute hypotension | University Tunis El Manar | Completed | Met primary |
| Phase 4 | NCT06076590 | Nov 2021 → May 2023 | acquired aneurysmal subarachnoid hemorrhage | Capital Medical University | Completed | No outcome recorded |
| Phase 4 | NCT05109000 | Nov 2021 → Jan 2022 | — | Jeffrey Alan Klein, MD | Unknown | No outcome recorded |
| Phase 4 | NCT03880903 | Jul 2020 → Mar 2021 | acute bronchiolitis | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT03068741 | Mar 2020 → Nov 2025 | infectious disease with sepsis | Dr. Damon Scales | Completed | No outcome recorded |
| Phase 4 | NCT04222816 | Jan 2020 → Dec 2021 | bipolar disorder | All India Institute of Medical Sciences, Bhubaneswar | Completed | Met primary |
| Phase 4 | NCT06114459 | Aug 2019 → Mar 2023 | — | Linkoeping University | Completed | No outcome recorded |
| Phase 4 | NCT02435069 | Feb 2016 → Mar 2017 | neurogenic bowel | Nemours Children's Clinic | Completed | Missed primary |
| Phase 4 | NCT02542241 | Nov 2015 → Sep 2018 | — | Fundacion Clinica Valle del Lili | Terminated | Missed primary Stop: Enrollment |
| Phase 4 | NCT03115060 | Apr 2015 → Apr 2018 | disorder of acid-base balance | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 4 | NCT02037815 | Jan → Apr 2014 | brain edema | Capital Medical University | Completed | Met primary |
| Phase 4 | NCT02233985 | Aug 2013 → Mar 2017 | acute bronchiolitis | Coordinación de Investigación en Salud, Mexico | Completed | No outcome recorded |
| Phase 4 | NCT02225431 | Sep 2012 → Apr 2015 | acute kidney injury | Ospedale Misericordia e Dolce | Completed | Met primary |
| Phase 4 | NCT01660867 | Aug 2012 → Dec 2014 | acute bronchiolitis | Seoul National University Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT00700375 | Jul 2008 → Mar 2010 | — | Osaka General Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01016249 | Apr 2007 → Apr 2008 | acute bronchiolitis | Hamad Medical Corporation | Completed | Met primary |
| Phase 4 | NCT00953940 | Jun 2005 → Feb 2011 | — | Hospital Universitario Ramon y Cajal | Terminated | Missed primary |
| Phase 4 | NCT03537989 | Nov 1999 → Aug 2001 | — | Holbaek Sygehus | Completed | Met primary |
| Phase 4 | NCT00493662 | — | dry eye syndrome | Innovative Medical | Completed | No outcome recorded |
| Phase not applicable34 trials · 3 missed | ||||||
| — | NCT07598188 | Jul 2026 → Jan 2027 expected | periapical periodontitis | Islamabad Medical and Dental College | Not yet recruiting | No outcome recorded |
| — | NCT07490808 | Mar → Jul 2026 overdue | acute kidney injury, atrial fibrillation | Beijing Anzhen Hospital | Recruiting | No outcome recorded |
| — | NCT07267897 | Mar → Jun 2026 overdue | — | Sakarya University | Not yet recruiting | No outcome recorded |
| — | NCT07452588 | Feb → Aug 2026 overdue | keratitis | Sohag University | Not yet recruiting | No outcome recorded |
| — | NCT07260240 | Dec 2025 → Mar 2026 | — | Queen Savang Vadhana Memorial Hospital, Thailand | Completed | No outcome recorded |
| — | NCT07486245 | Mar → Nov 2025 | pulpitis | CMH Multan Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT06343493 | Jun → Dec 2023 | chronic rhinosinusitis | Rawalpindi Medical College | Completed | No outcome recorded |
| — | NCT05921695 | May 2023 → Jun 2026 | — | Second Affiliated Hospital, School of Medicine, Zhejiang University | Terminated | No outcome recorded |
| — | NCT05707936 | Feb → Sep 2023 | — | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| — | NCT05980494 | Sep 2022 → May 2024 | infectious disease with sepsis | Fayoum University Hospital | Completed | No outcome recorded |
| — | NCT06950229 | Oct 2020 → Mar 2021 | — | Federal Teaching Hospital Abakaliki | Completed | No outcome recorded |
| — | NCT03685214 | Mar 2019 → Apr 2021 | acute kidney injury, infectious disease with sepsis | ZhiYong Peng | Unknown | Missed primary |
| — | NCT03563378 | Jul 2018 → May 2020 | biliary atresia intrahepatic syndromic form | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT03188614 | Aug 2017 → Sep 2018 | — | Southeast University, China | Unknown | No outcome recorded |
| — | NCT04215042 | May 2016 → Dec 2019 | acute kidney injury | Ospedale Misericordia e Dolce | Unknown | No outcome recorded |
| — | NCT03107598 | Mar → Sep 2016 | hypotensive disorder | University Hospital, Mahdia | Terminated | No outcome recorded |
| — | NCT02561325 | Sep 2015 → Jan 2017 | — | University Hospital, Clermont-Ferrand | Unknown | No outcome recorded |
| — | NCT02413125 | Feb → Jun 2015 | sinusitis | University of Virginia | Unknown | No outcome recorded |
| — | NCT02564016 | Oct 2014 → Sep 2016 | pregnancy disorder | Medical University of South Carolina | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT02172092 | Aug 2014 → Dec 2018 | diabetes mellitus | University Hospital, Linkoeping | Completed | No outcome recorded |
| — | NCT02112019 | Jun 2014 → Dec 2017 | Sjogren syndrome | Derk Jan Jager | Unknown | No outcome recorded |
| — | NCT02203123 | Mar 2014 → Apr 2015 | dehydration polycythemia | Seoul National University Hospital | Unknown | No outcome recorded |
| — | NCT02050295 | Feb 2014 → Jan 2018 | — | University of Alberta | Terminated | No outcome recorded |
| — | NCT01890252 | Jul 2013 → Jan 2014 | corneal edema | Eye-yon Medical | Completed | No outcome recorded |
| — | NCT02045238 | Jul 2013 → Dec 2014 | acute bronchiolitis | University of Sao Paulo | Terminated | No outcome recorded |
| — | NCT01823848 | Apr 2013 → Dec 2017 | constipation disorder | Children's Hospital Los Angeles | Terminated | No outcome recorded |
| — | NCT01654328 | Aug 2012 → Oct 2014 | — | Prof. Dr. J. Wetzels | Terminated | No outcome recorded |
| — | NCT01488448 | Nov 2011 → Jul 2014 | bronchiolitis | Montefiore Medical Center | Completed | Missed primary |
| — | NCT01449721 | Sep 2011 → Jan 2015 | infectious disease with sepsis | Christiana Care Health Services | Completed | Missed primary |
| — | NCT01128413 | Jul 2010 → Nov 2013 | — | Washington University School of Medicine | Terminated | No outcome recorded |
| — | NCT01000350 | Oct 2009 → Jun 2028 expected | postural orthostatic tachycardia syndrome | Vanderbilt University Medical Center | Active not recruiting | No outcome recorded |
| — | NCT01566084 | Feb 2009 → Jan 2012 | hypertensive disorder | University of Colorado, Boulder | Completed | No outcome recorded |
| — | NCT00474162 | May 2007 → Feb 2008 | — | University of British Columbia | Completed | No outcome recorded |
| — | NCT00353340 | Jan 2005 → Jan 2008 | acute kidney injury | Shaare Zedek Medical Center | Completed | No outcome recorded |
| Comparator or background therapy165 trials | ||||||
| Phase 0 | NCT05505708 Comparator | Dec 2022 → Jan 2023 | pulmonary edema | Kasr El Aini Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT03330704 Comparator | Nov 2017 → Jan 2020 | brain edema | Stanford University | Withdrawn | No outcome recorded |
| Phase 0 | NCT03246282 Background | Feb 2017 → Dec 2018 | — | John W. Reeves, MD | Suspended | No outcome recorded Stop: Business |
| Phase 0 | NCT02989571 Comparator | Mar 2016 → Dec 2020 | — | MemorialCare Health System | Completed | No outcome recorded |
| Phase 1 | NCT03340805 Comparator | Jan → Aug 2018 | — | Children's Hospital of Philadelphia | Completed | No outcome recorded |
| Show all 165 trials opens the full record — a long page | ||||||
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-08-05 | Baxter Healthcare Corporation | Baxter Issues Voluntary Nationwide Recall of One Lot of Heparin Sodium in 0.9% Sodium Chloride Injection Due to Potential for Elevated Endotoxin Levels baxter.com ↗ |
Evidence & citations 28 cited values
Every value below carries the sentence it was read from. 266 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sodium Chloride | “Following aspiration, an injection mixture consisting of 1 mL betamethasone,
1 mL of 2% lidocaine, and 1 mL of 0.9% isotonic sodium chloride is administered into the...” NCT07385560 ↗122“The aim of this study is to determine whether sodium bicarbonate is superior to sodium chloride in preventing contrast induced nephropathy in diabetic patients undergoing...” NCT00950079 ↗ “Treatment of the metabolic alkalosis with volume and sodium chloride (NaCl) replacement could reduce hypoventilation and hypercapnia, thereby improving symptoms, sleep patterns...” NCT00163852 ↗ “3% and 5% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, hypertonic solution for fluid and electrolyte replenishment in single dose containers for intravenous...” NCT04147182 ↗ “The Active Rinse is a 25 ml of Hypertonic Saturated Saline solution made by mixing 10 grams of Sodium Chloride (Table Salt) in 25 ml of Tap water with some salt crystals deposited.” NCT04842721 ↗ “0.9 percent sodium chloride will be administered via IV route to all subjects at a rate of 250 mL/hour for 4 hours prior to dosing with LPS and 8 hours after dosing with LPS.” NCT03306589 ↗ “Patients were randomized to receive intravenous volume supplementation with either (A) sodium chloride 0.9% 1 mL/kg/h for at least 12h prior and after the procedure” PMID 22267245 ↗ Jan 2012 “Patients received 4 mL of 3% sodium chloride (hypertonic saline [HS group]) or 0.9% sodium chloride (normal saline [NS group]) inhaled as many as 3 times in the ED.” PMID 24862623 ↗ Jul 2014 “0.9 % sodium chloride (NaCl) intravenous (IV) fluid replacement in children with moderate to severe dehydration secondary to acute gastroenteritis (AGE).” PMID 27480410 ↗ Aug 2016 “randomized to receive a 154-mEq/L infusion of either sodium chloride (n = 59) or sodium bicarbonate (n = 60) before and after iopamidol administration” PMID 15150204 ↗ May 2004 “The coload group received a sodium chloride 0.9% perfusion as rapidly as possible starting at the time of intrathecal injection for spinal anesthesia.” NCT03107598 ↗ |
| Known as | 0,9% NaCl | “After postoperative admission to the intensive care unit (ICU), patients will be randomly assigned to receive 5 ml/kg ideal body weight HS (7.3% NaCl) or normal saline (NS,...” PMID 31200756 ↗ Jun 20196“Normal saline (0.9% NaCl) is an isotonic solution that is widely used for intravenous application but is also used as our SOC for wound irrigation.” NCT01939145 ↗ “Sodium chloride (0.9%) referred as 0.9% NaCl for 72 hours post symptom onset (60-72 hourspost randomization)” NCT05869565 ↗ “Tranexamic Acid would be diluted in 0,9% Sodium Chloride (0,9% NaCl) to cumulative volume of 20 ml.” NCT03070847 ↗ “Normal Saline (0.9% NaCl)” NCT06953674 ↗ |
| Known as | 0.9% saline | “In Phase A, 12 subjects will receive 2 litres of 0.9% saline BP (Baxter Health Care, Thetford, UK) or Plasmalyte® (Baxter Health Care, Thetford, UK).” NCT01087853 ↗7“A total of 1500 ml 0.9% saline hydration therapy was administered over 2.5 hours.” NCT07286526 ↗ “Drug : ringer lactate, 0.9% saline, VOLUVEN ®” NCT01972828 ↗ |
| Known as | 0.9% sodium chloride | “Participants assigned to the hydration group will receive 0.9% sodium chloride intravenously at 2 mL/kg/h starting when the participant enters the electrophysiology laboratory...” NCT07490808 ↗ |
| Known as | 0.9% Sodium Chloride for Injection USP | “large quantity of ice-cold saline (0.9% Sodium Chloride for Injection USP) will be pumped as rapidly as possible into the aorta” NCT01042015 ↗ |
| Known as | 0.9% Sodium Chloride Saline | “Isotonic Saline ( 0.9% Sodium Chloride Saline)” NCT04213508 ↗ |
| Known as | 0.9% sodium chloride solution | “normal saline (0.9% sodium chloride solution)” NCT02590081 ↗ |
| Known as | 3% Sodium Chloride Saline | “Hypertonic Saline ( 3% Sodium Chloride Saline)” NCT04213508 ↗ |
| Known as | hypersel | “Hypertonic saline at the concentration of 3% (hypersel) has been injected for years into echinococcal cysts to kill live scolices” NCT04147182 ↗ |
| Known as | Hypertonic Saline | “Patients will receive inhaled Hypertonic Saline 3%, initially with a 2 hour interval, and clinical evaluation prior to each inhalation.” NCT02045238 ↗1“Hypertonic Saline ( 3% Sodium Chloride Saline)” NCT04213508 ↗ |
| Known as | Isotonic Saline | “Isotonic saline (NaCl 0.9%), called "physiological serum" is the standard fluid for the resuscitation of severely injured patients.” NCT03630224 ↗17“Isotonic Saline ( 0.9% Sodium Chloride Saline)” NCT04213508 ↗ |
| Known as | isotonic saline solution | “isotonic saline solution infusion (fluid preloading) to achieve correction of hypovolemia before spinal anesthesia using cardiac ultrasoud guidance by measurment of VTI...” NCT07108881 ↗ |
| Known as | NaCl | “Treatment of the metabolic alkalosis with volume and sodium chloride (NaCl) replacement could reduce hypoventilation and hypercapnia, thereby improving symptoms, sleep patterns...” NCT00163852 ↗10“dispersible NaCl powder, 8 mg per session per hour (one administration in each nostril and two oral inhalations)” NCT05196581 ↗ “supplemental 3ml 0.9% Sodium chloride (NaCl) solution in a nasal nebuliser once a day for 3 months” NCT03011632 ↗ “0.9% Sodium Chloride (NaCl) saline will be used as nasal irrigation for two groups.” NCT04213508 ↗ “50 mL of 10% hypertonic sodium chloride (NaCl)” NCT07596329 ↗ “0.9 % sodium chloride (NaCl)” PMID 27480410 ↗ Aug 2016 “Sodium Chloride (NaCl) 0.9 %” NCT07188766 ↗ “Normal Saline (0.9% NaCl)” NCT07486245 ↗ |
| Known as | NaCl 0.9% | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03630224 ↗ |
| Known as | Normal saline | “Drug: 0.9% Isotonic Saline (IS) 4 mL of IS will be administered via inhalation twice daily for 48 weeks The delivery system is the same as that for the test product.
Other...” NCT02950883 ↗83“The purpose of this study is to compare a large volume ACE flush using a salt water solution called normal saline with a small volume ACE flush using liquid glycerin.” NCT02435069 ↗ “Patient will receive normal saline or Ringer lactate or other balance salt solution during fluid resuscitation for shock reversal.” NCT02782819 ↗ “Normal saline will be give to subjects in the standard arm as the current standard of care for an initial resuscitation fluid” NCT01838863 ↗ “The placebo group is resuscitated with normal saline, the experimental group is resuscitated with balanced fluid.” NCT03188614 ↗ “Basal infusion of crystalloid (normal saline,Ringer's lactate,Ringer's solution)variable from 4 to 12 ml/kg/hour.” NCT01882920 ↗ “0.9% Normal Saline (0.9% Sodium Chloride) injection intravenously as needed.” NCT02668952 ↗ “stoma enemas (20mlkgdo of normal saline 3 times a day) will be prescribed” NCT02530346 ↗ “0.9% normal saline infusion and boluses of mannitol” NCT01111682 ↗ “normal saline, dextrose, lactated Ringer's” NCT02632630 ↗ “Drug: Normal saline” NCT05209841 ↗ |
| Known as | normal saline solution | “The aim of this study was to show that 6% hydroxyethyl starch (HES) 130/0.4 achieves a better resuscitation of the microcirculation than normal saline solution (SS), during...” PMID 20813485 ↗ Sep 20103“Ringer lactate solution (RLS) and normal saline solution (NSS) with dextrose water (D5W)” NCT06030609 ↗ “normal saline solution (0.9% sodium chloride)” NCT02707549 ↗ “Drug: Normal Saline Solution” NCT02785133 ↗ |
| Known as | Normal saline. Isotonic saline. Sodium Chloride 0.9% . | “Normal saline. Isotonic saline. Sodium Chloride 0.9% .” NCT00639912 ↗ |
| Known as | NSS | “Ringer lactate solution (RLS) and normal saline solution (NSS) with dextrose water (D5W)” NCT06030609 ↗ |
| Known as | PARI Hyper-Sal | “PARI Hyper-Sal™ Sodium Chloride Solution - 7%” NCT02276898 ↗ |
| Known as | physiological serum | “Isotonic saline (NaCl 0.9%), called "physiological serum" is the standard fluid for the resuscitation of severely injured patients.” NCT03630224 ↗ |
| Known as | saline | “Paramedics will administer up to 2 litres of intravenous saline (0.9%) to all patients regardless of systolic blood pressure, and reassessing this infusion after each 250ml are infused.” NCT03068741 ↗32“Isotonic or hypertonic saline or Ringer Lactate or any other crystalloids, at the necessary dose to restore hemodynamic for all ICU stay” NCT00318942 ↗ “Two types of fluids are commonly used. One is a salt water solution (saline) and the other is a starch water solution (pentastarch).” NCT00474162 ↗ “large quantity of ice-cold saline (0.9% Sodium Chloride for Injection USP) will be pumped as rapidly as possible into the aorta” NCT01042015 ↗ “Sodium chloride (0.9% saline) infusion is a sterile, non-pyrogenic solution of sodium chloride in Water for Injections.” NCT03829488 ↗ “administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure” NCT04243655 ↗ “0.9% saline as distension medium as long as diathermy is not in use” NCT03166228 ↗ “followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours.” NCT00749827 ↗ “saline (0.9% sodium chloride)” NCT06076590 ↗ |
| Known as | Saline and Listerine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04802408 ↗ |
| Known as | Saline solution | “If there is contraindication for administration of bicarbonate the pattern of intravenous hydration is performed with saline solution: 3 ml / kg / h for 1 hour before the...” NCT02872155 ↗3“Comparison of 6% hydroxyethyl starch 130/0.4 and saline solution for resuscitation of the microcirculation during the early goal-directed therapy of septic patients.” PMID 20813485 ↗ Sep 2010 |
| Known as | Sodium chloride injection | “Control group drug: Sodium chloride injection Manufacturer: Hua Run Shuang He Pharmaceutical Co., LTD.” NCT06076590 ↗ |
| Known as | Sodium chloride tablets | “Drug: Sodium chloride tablets” NCT01654328 ↗ |
| Known as | Table Salt | “The Active Rinse is a 25 ml of Hypertonic Saturated Saline solution made by mixing 10 grams of Sodium Chloride (Table Salt) in 25 ml of Tap water with some salt crystals deposited.” NCT04842721 ↗ |
| Modality | Other / unclassified | “crystalloid fluids (salt based, normal saline)” NCT00819416 ↗ |
| Route | Intravenous | “intravenous volume supplementation with either (A) sodium chloride 0.9%” PMID 22267245 ↗ Jan 2012 |